Life Sciences Products & Reviews

Primers and probes for MonkeyPox research

A panel consisting of primers designed to cover >98% of the RSV A, RSV B, Influenza A H1N1, Influenza A H3N2, Influenza B, and SARS-CoV-2 genomes. These primers obtain high levels of genome coverage from as low as 10–100 viral copies. xGen Amplicon Technology uses overlapping primer sets to provide comprehensive coverage in a single-tube, 2.5-hour workflow.

LiquidPlex panel is an advanced and user-friendly research assay for targeted next generation sequencing of circulating cell-free tumor DNA (ccfDNA/cfDNA/ctDNA) from 28 genes commonly associated with solid tumor type cancers.

FusionPlex Lung v2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 17 genes associated with NSCLC.

FusionPlex Core Solid Tumor is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 57 genes associated with various solid tumor malignancies.

FusionPlex Core Solid Tumor is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 57 genes associated with various solid tumor malignancies.

FusionPlex Pan Solid V2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 137 genes associated with various solid tumor malignancies.

VariantPlex Solid Tumor Focus V2 is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 20 genes associated with various solid tumor malignancies.

VariantPlex Core Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 60 genes associated with various solid tumor malignancies.

VariantPlex Expanded Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 76 genes associated with various solid tumor malignancies.

VariantPlex Pan Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, MSI, and TMB from 185 genes associated with various solid tumor malignancies.

VariantPlex Complete Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, MSI, and TMB from 430 genes associated with various solid tumor malignancies.

Immunoverse is a research assay that characterizes the immune repertoire, including assessment of T- and B-cell clonalities and rare clones, and detection of tumor infiltrating lymphocytes (TIL) and somatic hypermutation with targeted NGS of key T cell receptor and B cell receptor chain RNA relevant for blood cancer and solid tumor research.

VariantPlex Myeloid is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and ITDs from 75 genes associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS).

VariantPlex Core Myeloid is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and ITDs from 37 genes associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS).

FusionPlex Pan Heme is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 199 genes associated with lymphoid and myeloid malignancies.

FusionPlex Heme V2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 87 genes associated with lymphoid and myeloid malignancies.

FusionPlex Myeloid is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 84 genes associated with myeloid-origin malignancies.

FusionPlex Lymphoma is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 125 genes associated with lymphomas.

FusionPlex ALL is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 81 genes associated with acute lymphoblastic leukemia (ALL) .

Ideal for small scale in vitro applications, screening DsiRNA duplex pricing includes affinity purification.

Trifectin is a proprietary cationic lipid formulation that has been optimized for delivery of IDT’s Dicer-Substrate siRNAs into a wide variety of cell types with minimal toxicity.

For quantitative detection of human Cathepsin D in cell culture supernates, serum and plasma(heparin, EDTA).

For quantitative detection of human BDNF in cell culture supernates, serum and plasma(heparin, EDTA, citrate).

For quantitative detection of mouse BDNF in cell culture supernates, serum and plasma(heparin, EDTA, citrate).